Bayer is launching its Imaging Core Lab under the brand name Centafore. The package will support customers' clinical trials and Software as a Medical Device (SaMD) development.
Centafore provides technology and services for image management, processing, and interpretation. The company said this aims to empower study sponsors with expert project management and make way for advanced analyses of imaging data.
The package supports a range of therapeutic areas, including oncology, cardiovascular, central nervous system, dermatology, women’s health, pediatrics, and digital health. Centafore aims to help pharmaceutical, biotech, medical device, and digital health companies with early research through Phase IV trials and SaMD development. This also includes adherence to regulatory and data privacy compliance standards, Bayer said.
Bayer first presented its Imaging Core Lab Services at the 2024 European Congress of Radiology in Vienna, Austria. Bayer said that Centafore is currently being used in collaborations with Obio and Luxsonic Technologies.
The company plans to showcase Centafore at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, May 30 to June 1.
